---
layout: minimal-medicine
title: Meningococcal Group B Vaccine
---

# Meningococcal Group B Vaccine
### Generic Name
Meningococcal Group B Vaccine

### Usage

Meningococcal group B vaccine is used to actively immunize against invasive disease caused by *Neisseria meningitidis* serogroup B bacteria.  This serious bacterial infection can lead to meningitis (inflammation of the brain and spinal cord lining) and septicemia (blood infection), both potentially life-threatening conditions.  The vaccine is designed to prevent these infections.  While primarily used for preventing invasive meningococcal disease, its use might be considered in specific situations based on individual risk factors and public health recommendations (as determined by healthcare providers).

### Dosage

Dosage recommendations for meningococcal group B vaccine vary significantly depending on the specific vaccine formulation (MenB-4C or MenB-FHbp), the age of the recipient, their risk of exposure, and whether they are receiving the primary series or a booster.  The information below is for guidance only and should not replace consultation with a healthcare professional.  Always follow your doctor's or other qualified healthcare provider's instructions.  

**Adult Dosage:**  The recommended dosage is typically 0.5 mL administered intramuscularly (IM). However, the number of doses and the scheduling interval between doses differ greatly between the MenB-4C and MenB-FHbp vaccines and also depend on risk factors and public health guidance (such as during an outbreak).  A healthcare provider will determine the appropriate schedule based on your individual circumstances.  Booster doses may be recommended after the primary series to maintain protection.

**Pediatric Dosage:**  Vaccination strategies for children and adolescents vary widely, depending on age and risk factors, and also differ between MenB-4C and MenB-FHbp.   For example, the MenB-4C vaccine might be given in a 2-dose or 3-dose series depending on the age group (infants vs. older children), while MenB-FHbp may follow a 3-dose or 2-dose schedule.  Infants may have different schedules than older children and adolescents.  Again, consult your doctor for a detailed dosage plan.

**Dosage Adjustments:**  The manufacturer's labeling does not currently provide specific dosage adjustments for hepatic (liver) or renal (kidney) impairment.

### Side Effects

Common side effects (occurring in more than 10% of recipients) can include:

* Pain, redness, swelling, or tenderness at the injection site
* Headache
* Fatigue
* Muscle aches (myalgia)
* Joint pain (arthralgia)
* Fever
* Chills
* Nausea
* Vomiting
* Diarrhea
* Irritability (in infants)
* Drowsiness (in infants)
* Excessive crying (in infants)
* Changes in appetite

Less common but potentially serious side effects (occurring in less than 1% of recipients) have been reported, including:

* Allergic reactions (including anaphylaxis)
* Seizures
* Fainting (syncope)
* Skin rash
* Swelling of the eye
* Kawasaki syndrome (rare)

If any adverse effects occur, especially severe reactions, seek immediate medical attention.


### How it Works

Meningococcal group B vaccines work by stimulating the body's immune system to produce antibodies against specific components of the *N. meningitidis* serogroup B bacteria.  Different vaccines use different approaches. For example, MenB-4C uses a combination of recombinant protein antigens and outer membrane vesicles, while MenB-FHbp focuses on Factor H-binding protein.  These components trigger an immune response that helps the body recognize and fight off the bacteria should it encounter them in the future, thereby preventing infection.

### Precautions

* **Contraindications:** The vaccine is contraindicated (should not be given) to individuals with a known severe allergy to any component of the vaccine.
* **Interactions:** Some medications, like belimumab, eculizumab, fingolimod, immunosuppressants, and venetoclax, might interfere with the vaccine's effectiveness. Discuss all medications you are taking with your healthcare provider.
* **Warnings:**  There is an increased risk of fainting (syncope) and allergic reactions after vaccination.  Patients should be monitored for 15 minutes post-vaccination.  Pregnant women should generally defer vaccination unless their risk of infection is very high.  The decision to vaccinate during pregnancy should be carefully considered by healthcare providers.  Breastfeeding mothers can continue breastfeeding after receiving the vaccine.
* **Specific populations:**  The vaccine's use in vulnerable populations, such as infants and those with weakened immune systems, requires careful evaluation by a healthcare provider.  Close monitoring post-vaccination may be warranted for some.


### FAQs

* **Q: How effective is the meningococcal group B vaccine?** A:  The effectiveness varies depending on several factors including the specific vaccine, age group, and the circulating strains of the bacteria. Consult a healthcare professional for information regarding effectiveness in your specific circumstances.

* **Q: How long does the protection from the vaccine last?** A: The duration of protection varies and may require booster shots to maintain immunity.  A healthcare professional will advise on the optimal booster schedule.

* **Q: Can I get the meningococcal group B vaccine at the same time as other vaccines?** A: Generally, yes, unless contraindicated.  However, your healthcare provider will determine the best approach for your individual situation.

* **Q: What should I do if I experience side effects after receiving the vaccine?** A:  If you experience any concerning side effects, especially severe ones, seek immediate medical attention.  Minor side effects such as pain at the injection site can typically be managed with over-the-counter pain relievers.

* **Q: Is the vaccine safe for pregnant women?** A: The ACIP recommends deferring meningococcal group B vaccination during pregnancy unless the patient is at increased risk for meningococcal disease and the benefits outweigh the potential risks.

* **Q: Is the vaccine safe for breastfeeding mothers?** A:  Yes, breastfeeding mothers can continue breastfeeding after receiving the vaccine.

**Disclaimer:** This information is for general knowledge and should not be considered medical advice. Always consult with a qualified healthcare professional before making any decisions about your health or treatment.  This information is not exhaustive and may not cover all aspects of meningococcal group B vaccine.  Always refer to the most current prescribing information from your country's regulatory agency.
